A
Arcellx Inc
NASDAQ:ACLX
Arcellx Inc
NASDAQ:ACLX
Price:
69.38
USD
-0.12%
Market Closed
Market Cap:
$4B
Relative Value
The Relative Value of one ACLX stock under the Base Case scenario is 22.69 USD. Compared to the current market price of 69.38 USD, Arcellx Inc is Overvalued by 67%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ACLX
Relative Value
Base Case
22.69
USD
Overvaluation 67%
A
Multiples Across Competitors
ACLX Competitors Multiples
Arcellx Inc Competitors
Arcellx Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
A
|
Arcellx Inc
NASDAQ:ACLX
|
4B USD | 112.6 | -18.5 | -15.2 | -14.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
386.2B USD | 6.5 | 164.5 | 16 | 22.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.1B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.2B USD | 6.4 | 22.8 | 15.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.4B USD | 9.9 | 31.7 | 23.2 | 24.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.9B USD | 5.6 | 18 | 15.2 | 17.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD | 3.9 | 20.2 | 13.5 | 16.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.3B EUR | 13.9 | 32.6 | 55.5 | 57.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
